81 related articles for article (PubMed ID: 21533343)
21. Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
Bertolet BD
Drug Saf; 2004; 27 Suppl 1():11-8. PubMed ID: 15293849
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin induces apoptosis in Jurkat cells by mitochondria-dependent and mitochondria-independent mechanisms under normoxic and hypoxic conditions.
Mendivil-Perez M; Velez-Pardo C; Jimenez-Del-Rio M
Anticancer Drugs; 2015 Jul; 26(6):583-98. PubMed ID: 25734830
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro.
Hatano T; Ohkawa K; Matsuda M
Tumour Biol; 1993; 14(5):288-94. PubMed ID: 8235308
[TBL] [Abstract][Full Text] [Related]
24. Quinine circumvents the doxorubicin resistance of a multidrug resistant human leukemic cell-line, K562/DXR.
Solary E; Velay I; Chauffert B; Caillot D; Bidan JM; Dumas M; Casasnovas O; Guy H
Nouv Rev Fr Hematol (1978); 1990; 32(5):361-3. PubMed ID: 2099412
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic Effects of PEGylated Anti-EGFR Immunoliposomes Combined with Doxorubicin and Rhenium-188 Against Cancer Cells.
Hsu WC; Cheng CN; Lee TW; Hwang JJ
Anticancer Res; 2015 Sep; 35(9):4777-88. PubMed ID: 26254368
[TBL] [Abstract][Full Text] [Related]
26. Effects of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl] -2(1H)-quinolinone (OPC-8212), a new inotropic agent, on cardiotonic activity and coronary hemodynamics.
Inoue M; Hori M; Nakajima S; Kitakaze M; Fukunami M; Ishida Y; Abe H
Arzneimittelforschung; 1984; 34(3A):355-9. PubMed ID: 6540088
[TBL] [Abstract][Full Text] [Related]
27. Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone.
Frye RF; Tammara B; Cowart TD; Bramer SL
J Clin Pharmacol; 1999 Nov; 39(11):1177-83. PubMed ID: 10579149
[TBL] [Abstract][Full Text] [Related]
28. Immunoconjugates of doxorubicin and murine antihuman breast carcinoma monoclonal antibodies prepared via an N-hydroxysuccinimide active ester intermediate of cis-aconityl-doxorubicin: preparation and in vitro cytotoxicity.
Ogden JR; Leung K; Kunda SA; Telander MW; Avner BP; Liao SK; Thurman GB; Oldham RK
Mol Biother; 1989; 1(3):170-4. PubMed ID: 2604916
[TBL] [Abstract][Full Text] [Related]
29. Physico-chemical properties and stabilities of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl] -2(1H)-quinolinone (OPC-8212).
Shimizu T; Osumi T; Niimi K; Nakagawa K
Arzneimittelforschung; 1984; 34(3A):334-41. PubMed ID: 6540087
[TBL] [Abstract][Full Text] [Related]
30. Dexrazoxane abrogates acute doxorubicin toxicity in marmoset ovary.
Salih SM; Ringelstetter AK; Elsarrag MZ; Abbott DH; Roti EC
Biol Reprod; 2015 Mar; 92(3):73. PubMed ID: 25609833
[TBL] [Abstract][Full Text] [Related]
31. Vesnarinone-induced WBC disorders in Japan.
Matsuyama Y; Ohashi Y; Uchino H; Takaku F; Otsuka Y; Suzuki A
Pharmacoepidemiol Drug Saf; 1996 Mar; 5(2):87-93. PubMed ID: 15073836
[TBL] [Abstract][Full Text] [Related]
32. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.
Tolomeo M; Dusonchet L; Meli M; Grimaudo S; D'Alessandro N; Papoff G; Ruberti G; Rausa L
Cell Death Differ; 1998 Sep; 5(9):735-42. PubMed ID: 10200532
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of the cytotoxicity and selectivity of doxorubicin to hepatoma cells by synergistic combination of galactose-decorated γ-poly(glutamic acid) nanoparticles and low-intensity ultrasound.
Tsai WB; Lai HY; Lee JL; Lo CW; Chen WS
Langmuir; 2014 May; 30(19):5510-7. PubMed ID: 24754730
[TBL] [Abstract][Full Text] [Related]
34. Vesnarinone suppresses TNFα mRNA expression by inhibiting valosin-containing protein.
Hotta K; Nashimoto A; Yasumura E; Suzuki M; Azuma M; Iizumi Y; Shima D; Nabeshima R; Hiramoto M; Okada A; Sakata-Sogawa K; Tokunaga M; Ito T; Ando H; Sakamoto S; Kabe Y; Aizawa S; Imai T; Yamaguchi Y; Watanabe H; Handa H
Mol Pharmacol; 2013 May; 83(5):930-8. PubMed ID: 23393163
[TBL] [Abstract][Full Text] [Related]
35. Combined activity of interleukin-1 alpha or TNF-alpha and doxorubicin on multidrug resistant cell lines: evidence that TNF and DXR have synergistic antitumor and differentiation-inducing effects.
Borsellino N; Crescimanno M; Flandina C; Flugy A; D'Alessandro N
Anticancer Res; 1994; 14(6B):2643-8. PubMed ID: 7872695
[TBL] [Abstract][Full Text] [Related]
36. Enhanced chemosensitivity by simultaneously inhibiting cell cycle progression and promoting apoptosis of drug-resistant osteosarcoma MG63/DXR cells by targeting Cyclin D1 and Bcl-2.
Zhang C; Zhao Y; Zeng B
Cancer Biomark; 2012; 12(4):155-67. PubMed ID: 23568006
[TBL] [Abstract][Full Text] [Related]
37. Vesnarinone inhibits adenosine uptake in endothelial cells, smooth muscle cells and myocytes, and mediates cytoprotection.
Kitakaze M; Fong M; Yoshitake M; Minamino T; Node K; Okuyama Y; Terada N; Kambayashi T; Hori M
J Mol Cell Cardiol; 1997 Dec; 29(12):3413-7. PubMed ID: 9441846
[TBL] [Abstract][Full Text] [Related]
38. [Inotropic effect of novel domestic cardiotonic agent, vesnarinone--test in vitro].
Han W; Qin Y; Zhang Z; Zhou S; Yang Z
Hua Xi Yi Ke Da Xue Xue Bao; 1994 Sep; 25(3):316-20. PubMed ID: 7896252
[TBL] [Abstract][Full Text] [Related]
39. Doxorubicin activity is enhanced by hyperthermia in a model of ex vivo vascular perfusion of human colon carcinoma.
Pilati P; Mocellin S; Rossi CR; Scalerta R; Alaggio R; Giacomelli L; Geroni C; Nitti D; Lise M
World J Surg; 2003 Jun; 27(6):640-6. PubMed ID: 12734680
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of hexamethylenetetramine in combination with chemotherapy using free and pegylated liposomal doxorubicin in vivo, referring to the effect on quiescent cells.
Masunaga S; Kono K; Nakamura J; Tano K; Yoshida H; Watanabe M; Kashino G; Suzuki M; Kinashi Y; Liu Y; Ono K
Oncol Rep; 2009 May; 21(5):1307-12. PubMed ID: 19360308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
